Home›Compare›Raeliva vs UrWay Health

Raeliva vs UrWay Health: Which Is Better?

Head-to-head comparison of Raeliva and UrWay Health based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

UrWay Health scores higher overall in our independent evaluation (64.4/100 vs 61.2/100), leading on experience, product range, reputation. Raeliva comes out ahead on value. Raeliva has the lower entry price (from $117/mo vs $166/mo), so the better value depends on which treatment you need.

61

Raeliva is a 2026-launched GLP-1 and longevity storefront built on the CareValidate platform, with flat dose-independent pricing and prepay discounts.

Visit Raeliva

UrWay Health is a New Jersey-based cash-pay telehealth storefront selling all-inclusive compounded GLP-1s, NAD+, glutathione, sermorelin and ED injections with no membership fee.

Visit UrWay Health

Score Breakdown

DimensionRaelivaUrWay Health
Overall Score61.2/10064.4/100 ✓
Trust & Safety30%60/10060/100
Value25%72/100 ✓70/100
Experience20%62/10070/100 ✓
Product Range15%55/10058/100 ✓
Reputation10%45/10062/100 ✓

At a Glance

Founded20262023
HeadquartersSan Diego, CAShrewsbury, NJ
Publicly tradedNoNo
Treatment categories24
Treatments listed76
Starting price$117/mo$166/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryRaelivaUrWay Health
Weight Loss / GLP-1$150–$219
Compounded Semaglutide Injections
$166–$249
Compounded Semaglutide + B12
Longevity & Peptides$117–$179
NAD+
$179–$199
NAD+ Injections

Raeliva

+Clear operator disclosure: names the platform operator, the billing/intake vendor (CareValidate), the medical group (Lion MDs, with physician NPIs) and six dispensing pharmacies
+Flat pricing at every dose for semaglutide and tirzepatide, published on each product page
+Accepts transfers at the patient's current GLP-1 dose after provider review, with no charge if not eligible
−Launched in 2026 with ~1,500 claimed patients and only 12 Trustpilot reviews, all five-star and posted within two months
−Lowest advertised rates require 6- or 12-month prepayment ($900–1,450 upfront), and dispensed medication is non-refundable
−Runs on CareValidate's white-label telehealth stack, so the clinical and billing experience is shared with other storefronts
Read the full Raeliva review →

UrWay Health

+All-inclusive pricing (medication, consult, supplies, overnight shipping) shown on the homepage with no membership fee
+Solid Trustpilot record for its size: 4.6/5 across ~471 reviews, 85% five-star, with shipping speed and support responsiveness cited most
+Most approved orders ship within one business day, with 12-week GLP-1 plans that lower the effective monthly cost
−No prescribing medical group, medical director or dispensing pharmacy is named anywhere on the site
−Pharmacy ships Monday–Thursday only, so approvals late in the week wait until the following Monday
−Some reviewers report inconsistent results between vials and difficulty getting dosing right
Read the full UrWay Health review →

Raeliva vs UrWay Health — FAQ

Is Raeliva better than UrWay Health?

▾

UrWay Health scores higher overall in our independent evaluation (64.4/100 vs 61.2/100), leading on experience, product range, reputation. Raeliva comes out ahead on value. Raeliva has the lower entry price (from $117/mo vs $166/mo), so the better value depends on which treatment you need.

Is Raeliva or UrWay Health cheaper?

▾

Raeliva has the lower starting price (from $117/mo vs $166/mo for UrWay Health). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do Raeliva and UrWay Health both offer?

▾

Both platforms treat Weight Loss / GLP-1, Longevity & Peptides. Raeliva covers 2 treatment categories total and UrWay Health covers 4.

Still deciding?